This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Cellectis (NASDAQ:CL

Analysts downgraded several stocks: HSBC cut Banco Santander Brasil (BSBR) to Hold with a $6.2 target; Rosenblatt downgraded Ribbon Communications (RBBN) to Neutral with a $2.2 target; Citizens downgraded Cellectis (CLLS) to Market Perform; Barclays downgraded Scholar Rock (SRRK) to Equal-Weight with a $58 target; Raymond James downgraded Ascendis Pharma (ASND) to Outperform with a $287 target.

Original reporting
Published Sep 15, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 5:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CLLS
Bearish
medium confidence
Mentioned
$CLLS · $BSBR · $RBBN · $SRRK · $ASND
Relevance
6/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$CLLSBearishMed
01

Why it matters

The downgrades may lead to short-term price pressure on the affected stocks, though the overall market impact is limited.

02

Market read

Downgrades may trigger modest sell-offs in the listed stocks, with limited broader market effect.

03

What to watch

Potential upcoming earnings or sector catalysts could offset downgrade effects.

Relevance 6/10Novelty 6/10Timing: after Monday close

Background

Analyst rating changes are a routine part of market coverage, reflecting updated views on company prospects.

Company-level read

Ticker impact

$CLLSBearishMedium confidence
Context

Cellectis (NASDAQ:CLLS) was downgraded from Market Outperform to Market Perform.

Expected impact

Potential short-term decline

Evidence & confidence

Downgrade signals weaker outlook, likely prompting sell pressure.

$BSBRNeutralMedium confidence
Context

Banco Santander Brasil (NYSE:BSBR) was downgraded from Buy to Hold.

Expected impact

Flat to slight down

Evidence & confidence

Hold suggests no further upside, may temper buying.

$RBBNBearishMedium confidence
Context

Ribbon Communications (NASDAQ:RBBN) was downgraded from Buy to Neutral.

Expected impact

Possible modest decline

Evidence & confidence

Neutral stance often leads to reduced demand.

$SRRKNeutralMedium confidence
Context

Scholar Rock Holding (NASDAQ:SRRK) was downgraded from Overweight to Equal-Weight.

Expected impact

Flat to slight down

Evidence & confidence

Equal-Weight is a neutral stance, limiting upside.

$ASNDNeutralMedium confidence
Context

Ascendis Pharma (NASDAQ:ASND) was downgraded from Strong Buy to Outperform.

Expected impact

Flat to modest decline

Evidence & confidence

Reduced rating may temper enthusiasm.

Market effects

Analyst downgrades across diverse sectors may signal broader caution.

Primarily U.S. listed equities; limited regional effect.

Low global impact beyond individual stocks.

Counterpoint

Some investors may view the downgrades as overreaction and look for buying opportunities.

Key entities

  • Cellectis SA

    Biotech firm focused on gene editing.

  • Banco Santander Brasil

    Brazilian banking subsidiary of Santander.

  • Ribbon Communications

    Provider of communications software.

  • Scholar Rock Holding Corp

    Life sciences contract research organization.

  • Ascendis Pharma

    Biopharmaceutical company.

Related articles

$CLLSMedAI 8/10

Cellectis Earnings Call Highlights In Vivo Editing Shift

Cellectis (CLLS) reported Q3 earnings, highlighting a shift to in vivo gene editing. Preclinical results for HEAL-101 and HEAL-201 showed promise, with HEAL-101 reducing APOC3 levels by 67% and triglycerides by 76% in mice. The company expects clinical data in 2027-2028. Revenue fell to $19.9M, but net income improved to a $5.2M gain. Cash runway extends into 2H 2028. Management also announced workforce reductions and discontinued legacy programs.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$CLLSMed

What Cellectis (CLLS) Said on Its Q3 Earnings Call

Cellectis (CLLS) reported Q3 earnings, highlighting HEAL-201's potential in reducing PCSK9 levels and plans for a Phase 1 trial. The company expects to cut global headcount by up to 70% in 2026-2027. Revenues fell to $19.9M from $67.4M YoY, while R&D expenses rose to $108.8M. Cash reserves were $149M as of Sept. 30, down from $211M at the end of 2025.

$ASNDMed

TD Cowen raises Ascendis Pharma stock price target on revenue beat

TD Cowen raised its price target for Ascendis Pharma (ASND) to $352, citing strong Q3 revenue beats across its products. Revenue grew 86% YoY with a 92% gross margin. The company reaffirmed long-term revenue targets of €5B by 2030 and €10B by 2035. ASND stock trades near its 52-week high at $266.31. Other analysts also raised targets and maintained positive ratings.

$CLLSMedAI 8/10

Cellectis Reports Third-Quarter 2026 Results and In Vivo Editing Data

Cellectis SA reported Q3 2026 results with $149M in cash, $19.9M revenue (down from $67.4M), and increased R&D expenses to $108.8M. Preclinical data showed promising results for .HEAL-101 and .HEAL-201. The company is shifting focus to in vivo gene editing, discontinuing lasme-cel and eti-cel programs. Analysts rate CLLS stock as Buy with $8.00 target, while TipRanks' AI rates it Neutral.